ArticleGastroenterology2011

DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.

Shoumin Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.